Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Epstein

Gastroenterology Annapolis, MD Medical Doctor

NPI 1942238928 CMS profile 178925

621 Ridgely Ave, Suite 201, Annapolis, MD 21401

Open in the dashboard

General payments

$162,082

719 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,246,249 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Michael Epstein of Annapolis, MD is reported in the CMS Open Payments database as having received $162,082 across 719 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,246,249 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $89 2
2023 General $3,182 68
2022 General $26,281 171
2021 General $39,988 153
2020 General $31,166 131
2019 General $61,377 194

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Epstein
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Michael Epstein were reported at $89. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Michael Epstein Gastroenterology median Middle half National median
2019 $61,377 $417 $126–$1,100 $163
2020 $31,166 $224 $74–$624 $114
2021 $39,988 $352 $106–$1,054 $132
2022 $26,281 $448 $129–$1,270 $149
2023 $3,182 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $89 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $57,810 88 payments
  2. Amgen Inc. $33,480 53 payments
  3. Pfizer Inc. $25,450 69 payments
  4. E.R. Squibb & Sons, L.L.C. $12,078 10 payments
  5. RedHill Biopharma Inc. $10,320 34 payments
  6. Daiichi Sankyo Inc. $3,806 15 payments
  7. Celgene Corporation $3,627 17 payments
  8. Gilead Sciences, Inc. $2,751 18 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,699 61 payments
  10. AbbVie, Inc. $2,410 135 payments
  11. Other $7,652 219 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $68,997 95 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $66,853 32 payments
  3. Travel and Lodging $13,498 46 payments
  4. Food and Beverage $11,274 542 payments
  5. Honoraria $1,385 2 payments
  6. Education $76 2 payments
Products named General payments · program years 2019–2025
  1. AVSOLA $33,480 53 payments
  2. INFLECTRA $17,570 37 payments
  3. ZEPOSIA $12,705 25 payments
  4. Talicia $10,300 33 payments
  5. XELJANZ $7,886 33 payments
  6. INJECTAFER $3,705 9 payments
  7. IBSRELA $2,160 13 payments
  8. PLENVU $1,739 6 payments
  9. HUMIRA $927 51 payments
  10. Monoferric $876 3 payments
  11. Other $8,631 436 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

65

Median for Internal Medicine: 777

Drug cost

$2,840

Median for Internal Medicine: $73,373

Branded share of claims

40%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Esomeprazole Magnesium Generic 13 $1,932
Lansoprazole Generic 13 $494
Lactated Ringers Ringer's Solution,lactated Brand 26 $250
Pantoprazole Sodium Generic 13 $163

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

719 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record